Tirzepatide therapy significantly reduced the incidence of HALT (8.4% vs 21.6%, p=0.002) and ≥ mild paravalvular leak (10.7% vs 25.3%, p=0.006) at 6 months in obese patients undergoing TAVR.
RCT (n=260)
Open-label
Randomized
Yes
Does tirzepatide therapy reduce the incidence of HALT and PVL in obese patients undergoing TAVR?
Tirzepatide therapy significantly improves post-TAVR valve healing and hemodynamics by reducing subclinical leaflet thrombosis and paravalvular leak in obese patients.
Absolute Event Rate: 8.4% vs 21.6%
p-value: p=0.002
BACKGROUND: Obesity is increasingly recognized as a critical modifier of outcomes following transcatheter aortic valve replacement (TAVR), predisposing patients to subclinical leaflet thrombosis (SLT), hypo-attenuated leaflet thickening (HALT), and paravalvular leak (PVL). Metabolic inflammation, endothelial dysfunction, and pro-thrombotic states associated with obesity contribute to impaired bioprosthetic valve healing. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated robust metabolic, anti-inflammatory, and vascular protective effects. However, its impact on post-TAVR valve performance has not been previously evaluated. OBJECTIVES: To determine whether tirzepatide therapy initiated before TAVR and continued post-procedure reduces the incidence of HALT and PVL in obese patients undergoing TAVR. METHODS: TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m RESULTS: Among 260 randomized patients, tirzepatide therapy significantly reduced HALT incidence (8.4% vs 21.6%, p = 0.002) and ≥ mild PVL (10.7% vs 25.3%, p = 0.006) at 6 months. Tirzepatide was associated with marked reductions in CRP and body weight without an increase in major bleeding. Multivariable analysis identified tirzepatide use, CRP reduction >30%, and BMI <32 kg/m CONCLUSIONS: Metabolic modulation with tirzepatide significantly improves post-TAVR valve healing and hemodynamics in obese patients. These findings introduce a novel cardio-metabolic strategy to reduce structural valve complications following TAVR. TRIAL SUMMARY: TAVR-MET STUDY: The TAVR-MET trial was a prospective, randomized, multicenter study designed to evaluate whether metabolic modulation with tirzepatide, a dual GIP/GLP-1 receptor agonist, could improve bioprosthetic valve outcomes following transcatheter aortic valve replacement (TAVR) in obese patients. Obesity is increasingly recognized as a key determinant of post-TAVR complications, particularly subclinical leaflet thrombosis (HALT) and paravalvular leak (PVL), driven by chronic inflammation, endothelial dysfunction, and a prothrombotic state. Tirzepatide has demonstrated potent weight-reducing, anti-inflammatory, and vascular protective effects, but its role in structural valve outcomes had not previously been explored. The trial enrolled 260 obese patients (BMI ≥ 30 kg/m
Thirugnanam et al. (Sun,) conducted a rct in Obesity in patients undergoing TAVR (n=260). Tirzepatide was evaluated on Incidence of hypo-attenuated leaflet thickening (HALT) (p=0.002). Tirzepatide therapy significantly reduced the incidence of HALT (8.4% vs 21.6%, p=0.002) and ≥ mild paravalvular leak (10.7% vs 25.3%, p=0.006) at 6 months in obese patients undergoing TAVR.